Modality
Radioligand
MOA
JAK1i
Target
Nectin-4
Pathway
T-cell
Gastric Ca
Development Pipeline
Preclinical
Jan 2017
→ Jan 2030
PreclinicalCurrent
NCT08117761
2,636 pts·Gastric Ca
2017-01→2030-01·Not yet recruiting
NCT08196959
1,750 pts·Gastric Ca
2022-07→TBD·Active
4,386 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-049mo agoConference· Gastric Ca
2030-01-153.8y awayInterim· Gastric Ca
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Not yet…
Preclinical
Active
Catalysts
Conference
2025-07-04 · 9mo ago
Gastric Ca
Interim
2030-01-15 · 3.8y away
Gastric Ca
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08117761 | Preclinical | Gastric Ca | Not yet recr... | 2636 | FEV1 |
| NCT08196959 | Preclinical | Gastric Ca | Active | 1750 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα |